SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Peer-reviewed published articles

17 Jan 2013 07:00

RNS Number : 7246V
Tristel PLC
17 January 2013
 



Tristel plc

("Tristel")

 

Peer-reviewed published articles supporting Tristel's technology and products

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces the publication of two articles in peer-reviewed journals that describe the benefits of Tristel products.

 

The first is titled "Guidelines for Reprocessing Non-lumened Heat-Sensitive Ear/Nose/Throat Endoscopes" and has been published in The Laryngoscope, the journal of The American Laryngological, Rhinological and Otological Society (Laryngoscope , 122:1708-1718, 2012). The article proposes the standardisation of disinfection procedures for ENT endoscopes and reviews a number of technologies including Tristel's Wipes System, Stella decontamination system and Shine automated washer-disinfector. 

 

The second publication is of a study undertaken in the Prince of Wales Hospital, Hong Kong, and is titled "Transvaginal ultrasound probe contamination by the human papillomavirus in the emergency department" (Emergency Medicine Journal, July 2012). The study revealed the prevalence of human papillomavirus (HPV) on the ultrasound equipment used routinely in the hospital and indicated that existing disinfection methods were inappropriate. The hospital has adopted the Tristel Wipes System to improve its decontamination process. 

 

Tristel CEO, Paul Swinney, commented: "We believe the Wipes System is now gaining recognition as the "gold standard" for ENT endoscopes in countries where it has been approved for use, which include all those in the European Community, Australia and many countries in the Far East. Whilst we have not attempted to register the Wipes System in the United States, its inclusion in The Laryngoscope review of decontamination methodologies, which is the most widely read journal for ENT worldwide, is a significant benefit to the marketing of our product.

 

"A second area in the hospital where the Wipes System is achieving rapid uptake in the United Kingdom and Australia is ultrasound. The Prince of Wales study joins a growing body of scientific evidence that existing methods of disinfecting intra-vaginal and rectal ultrasound probes are inadequate. The Wipes System is considered to be a more effective method of disinfection. In terms of patient procedures, and therefore disinfectant use, ultrasound is as large a market as digestive and respiratory medicine where almost all the attention of the infection control market has been focused for the past twenty years. Our product strategy of focusing on the smaller non-lumened instruments used in ENT and ultrasound positions us well for continued growth in this area."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Lianne Cawthorne

Mob: 07854 391 303 or lianne.cawthorne@walbrookpr.com

finnCap

Tel: 020 7600 1658

Geoff Nash (Corporate Finance)

Charlotte Stranner (Corporate Finance)

Simon Starr (Corporate Broking)

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASFUFMMFDSEDF
Date   Source Headline
1st Nov 20194:00 pmRNSAudited accounts and notice of AGM
30th Oct 20192:25 pmRNSIssue of Equity
16th Oct 20197:00 amRNSFinal Results
14th Oct 201911:43 amRNSIssue of Equity
13th Sep 20193:58 pmRNSIssue of Equity
10th Sep 201910:27 amRNSHolding(s) in Company
28th Aug 20197:00 amRNSIssue of Equity
21st Aug 20197:00 amRNSInvestor results presentation
7th Aug 201910:31 amRNSIssue of Equity
31st Jul 20193:45 pmRNSHolding(s) in Company
22nd Jul 20197:00 amRNSTrading update, Acquisition & Notice of Results
12th Jun 20197:00 amRNSIssue of Equity
5th Jun 20197:00 amRNSShareholder Open Day
17th May 20191:58 pmRNSIssue of Equity
10th May 201910:26 amRNSHolding(s) in Company
1st Apr 20197:00 amRNSRegulatory approvals in China and South Korea
26th Mar 20197:00 amRNSHolding(s) in Company
6th Mar 20197:00 amRNSIssue of Equity
4th Mar 20192:31 pmRNSIssue of Equity and PDMR Dealing
1st Mar 20193:42 pmRNSDirector/PDMR Shareholding
25th Feb 20197:00 amRNSHalf-year Report
5th Feb 20197:00 amRNSDirector Appointment
14th Jan 20195:26 pmRNSDirector/PDMR Shareholding
14th Jan 201912:00 pmRNSInvestor results presentation
11th Dec 201810:49 amRNSResult of AGM
11th Dec 20187:00 amRNSAGM Statement and notice of results
19th Nov 201811:31 amRNSDirector/PDMR Shareholding
19th Nov 20187:00 amRNSAcquisition & Board Appointment
5th Nov 20188:35 amRNSIssue of Equity
17th Oct 20187:00 amRNSFinal Results
13th Sep 20187:00 amRNSNotice of Results
24th Aug 20187:00 amRNSIssue of Equity
23rd Aug 20187:00 amRNSIssue of Equity
19th Jul 20184:21 pmRNSHolding(s) in Company
19th Jul 20183:55 pmRNSHolding(s) in Company
16th Jul 20185:49 pmRNSResult of secondary placing
16th Jul 20181:53 pmRNSProposed secondary placing of Ordinary Shares
13th Jul 20187:00 amRNSTrading update & Notice of results
12th Jun 20184:39 pmRNSIssue of Equity
11th Jun 20182:37 pmRNSDirector/PDMR Shareholding
8th Jun 20187:00 amRNSShareholder Open Day
7th Jun 20188:15 amRNSIssue of Equity
1st Jun 20183:50 pmRNSDirector/PDMR Shareholdings
15th May 20188:14 amRNSHolding(s) in Company
11th May 20185:45 pmRNSDirector/PDMR Shareholding
10th May 20188:26 amRNSHolding(s) in Company
8th May 20189:51 amRNSIssue of Equity
2nd May 20184:55 pmRNSDirector/PDMR Dealing and Issue of Equity
23rd Apr 20187:00 amRNSEPA approval received
13th Apr 20182:55 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.